Pharmacological characterization of 2‐methoxy‐N‐propylnorapomorphine's interactions with D2and D3dopamine receptors

Authors:

Abstract
Dopaminergic signaling pathways have been extensively investigated using PET imaging, primarily with antagonist radioligands of D2and D3dopamine receptors (DARs). Recently, agonist radioligands of D2/D3DARs have begun to be developed and employed. One such agonist is (R)‐2‐11CH3O‐N‐n‐propylnorapomorphine (MNPA). Here, we perform a pharmacological characterization of MNPA using recombinant D2and D3DARs expressed in HEK293 cells. MNPA was found to robustly inhibit forskolin‐stimulated cAMP accumulation to the same extent as dopamine in D2or D3DAR‐transfected cells, indicating that it is a full agonist at both receptors. MNPA is ∼50‐fold more potent than dopamine at the D2DAR, but equally potent as dopamine at the D3DAR. MNPA competition binding curves in membrane preparations expressing D2DARs revealed two binding states of high and low‐affinity. In the presence of GTP, only one binding state of low affinity was observed. Direct saturation binding assays using [3H]MNPA revealed similar results as with the competition experiments leading to the conclusion that MNPA binds to the D2DAR in an agonist‐specific fashion. In contrast to membrane preparations, using intact cell binding assays, only one site of low affinity was observed for MNPA and other agonists binding to the D2DAR. MNPA was also found to induce D2DAR internalization to an even greater extent than dopamine as determined using both cell surface receptor binding assays and confocal fluorescence microscopy. Taken together, our data indicate that the PET tracer, MNPA, is a full and potent agonist at both D2and D3receptors. Synapse 63:462–475, 2009.

This publication has 61 references indexed in Scilit: